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ABSTRACT
Objectives: The objective of this research was to estimate
lifetime cost-effectiveness of treating patients with cinacalcet
early (when parathyroid hormone [PTH] levels are in the
range of 300–500 pg/ml) versus delaying treatment with
cinacalcet (cinacalcet initiated when PTH levels are >800 pg/
ml) in patients with secondary hyperparathyroidism (SHPT)
in the US setting.
Methods: A Markov model was developed to simulate the
effects of early versus delayed use of cinacalcet (plus standard
of care). Four different PTH ranges (300 pg/ml; 301–
500 pg/ml; 501–800 pg/ml; >800 pg/ml) were used to repre-
sent four different health states within the Markov model.
Associated with each Markov state (PTH range) were varying
risks of major SHPT complications, including cardiovascular
disease (CVD), fracture (Fx), and parathyroidectomy (PTx).
Baseline cohort characteristics and risks of CVD, Fx, and
PTx by PTH category were derived from a large US renal
database and published sources. Costs were estimated from
the US Renal Data System database and reported in 2006 US
Dollars ($). Clinical and economic outcomes were discounted
at 3.0% per annum.
Results: Early treatment was projected to improve quality-
adjusted life years (QALYs) by 0.337 years compared to
delaying treatment. The incremental cost-effectiveness ratio
was $17,275 per QALY gained.
Conclusions: Early treatment with cinacalcet was associated
with improvements in QALYs and would represent good
value for money compared to delaying treatment with
cinacalcet.
Keywords: cinacalcet, cost-effectiveness, cost, ESRD, model-
ing, secondary hyperparathyroidism, US.
Introduction
End-stage renal disease (ESRD), deﬁned as a life-
threatening reduction in renal function requiring dialy-
sis or a renal transplant, affects over 335,000 patients
in the USA [1]. Recent estimates from the US Renal
Data System (USRDS) have shown that treating ESRD
patients is a considerable burden on health-care
payers, exceeding $20 billon or approximately 6.7%
of the total Medicare budget [2]. Cardiovascular
disease (CVD) in this population continues to be the
single largest cause of mortality and morbidity,
accounting for about 45% percent of all deaths [2] and
as much as one-third of the hospitalizations. Numer-
ous cardiovascular (CV) risk factors are present in
patients with kidney disease, including hypertension,
extracellular ﬂuid volume overload, diabetes, glucose
intolerance, dyslipidemia, and alterations in homocys-
teine metabolism [1,3–7]. Nevertheless, even when
these factors are considered together with other estab-
lished CV risk factors, including advanced age, gender,
obesity, and tobacco use, the risk for CV mortality in
patients with advanced kidney disease exceeds that
which would be predicted [4,8,9].
Common among patients with ESRD are high levels
of parathyroid hormone (PTH) (secondary hyperpar-
athyroidism [SHPT]), and an imbalance of calcium
and phosphorus metabolism [10], which are all closely
linked to CV morbidity and mortality [11–15]. Several
studies have found that increased levels of PTH are
associated with an increased risk of both CVD mor-
bidity and mortality [4,15–18]. Similarly, associations
between increased levels of calcium (Ca) [15,16,19],
phosphorus (P) [15–19], and calcium-phosphorus
product (Ca ¥ P) [15,17,19] and an increased risk of
both CVD morbidity and mortality have been estab-
lished [4].
The National Kidney Foundation’s Kidney Disease
Outcomes Quality Initiative (K/DOQI™) has recently
published guidelines for patients with SHPT, in an
attempt to improve their management. The K/DOQI
guidelines recommend that patients be treated to PTH
levels between 150 and 300 pg/ml, corrected serum
calcium levels of 8.4 to 9.5 mg/dl, serum phosphorus
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of 3.5 to 5.5 mg/dl, and Ca ¥ P levels below 55 mg2/dl2
[20]. Historically, treatments for patients with SHPT
included restricted phosphate consumption, oral phos-
phate binders, and calcium and vitamin D supplements
[21–24]. Nevertheless, the complex metabolic relation-
ship between PTH, Ca, and P makes treatment difﬁ-
cult, oftentimes with one or more of the treatments
canceling out the effect of another [25–28].
A recent advancement to the historical treatments
is cinacalcet HCL (cinacalcet), a calcimimetic, which
has been demonstrated to control all four biomarkers
linked to CV morbidity and mortality (PTH, Ca, P, and
Ca ¥ P) [24,29–33]. Currently in the USA, the use of
cinacalcet is skewed toward patients with more severe
PTH levels. Nevertheless, recent studies have indicated
that treating patients with cinacalcet early (before PTH
levels become severely uncontrolled) may be clinically
beneﬁcial [20]. Pooled data from three, similarly
designed, 26-week clinical trials with a total 1136
patients randomized to receive either cinacalcet or
placebo in addition to standard of care indicated that
cinacalcet-treated patients were more likely to reach
K/DOQI target ranges than those receiving placebo
[24]. Further analysis also revealed that the patients
who were administered cinacalcet for PTH levels
between 300 and 500 pg/ml had a larger proportion of
them reaching K/DOQI targets as compared to the
patients who were administered cinacalcet for PTH
levels between 500 and 800 pg/ml (or >800 pg/ml).
Given that uncontrolled PTH levels have been associ-
ated with increased risk of mortality, CVD, and frac-
ture events, there may be a sound clinical rationale for
the early initiation of cinacalcet treatment, before PTH
levels become substantially elevated [4,29,34].
Therefore, we performed a simulation modeling
analysis based on the available clinical data to evaluate
the cost-effectiveness of early treatment with cinacalcet
(initiated when PTH levels were between 300 and
500 pg/ml) compared to delaying treatment (initiated
once PTH levels increased above 800 pg/ml) in ESRD
patients with SHPT.
Methods
Model
A Markov model was developed in TreeAge Pro 2006
0.4 (TreeAge Software, Williamstown, MA) to
compare two treatment regimens in patients with
ESRD and SHPT. The two treatment regimens simu-
lated in the model were: 1) early treatment with cina-
calcet in addition to standard of care (phosphate
binders and vitamin D sterols)—with cinacalcet
treatment initiated at the start of the simulation and
then maintained over patient lifetimes; and 2) stand-
ard of care followed by delayed treatment with
cinacalcet—with cinacalcet treatment initiated once
PTH-levels increased above 800 pg/ml and then main-
tained over patient lifetimes. Cinacalcet lowers all four
key K/DOQI targets; however, it is indicated for the
treatment of SHPT based on PTH levels, and therefore,
the model was constructed accordingly to account for
the effect of cinacalcet by patients’ current PTH levels.
The model was designed to estimate life expectancy
and quality-adjusted life expectancy, and account for
the direct medical costs associated with each treatment
regimen and treating disease-related complications.
Four PTH ranges (below 300 pg/ml, 301–500 pg/
ml, 501–800 pg/ml, and above 800 pg/ml) were used
to represent four different health states within the
model. Associated with each health state (PTH range)
were differential risks of developing complications
because of SHPT (CVD event, fracture, parathyroidec-
tomy) and all cause mortality. Simulated patients in
both treatment regimens were assumed to enter the
model with PTH levels between 301 and 500 pg/ml,
and then transition to other PTH levels according to
their respective treatment regimen. The cycle length of
the model was 6 months.
If patients in the model experienced a CVD event or
a major fracture, the costs of hospitalization related
to its management were applied. Associated follow-up
and maintenance costs in subsequent cycles, however,
were not captured in the present analysis. These
patients also experienced a reduction in their quality of
life after CVD events or fractures. Patients who under-
went a parathyroidectomy procedure were assumed to
undergo immediate hospitalization for surgery. They
incurred a reduction in quality of life for the year after
surgery and then they assumed the quality of life asso-
ciated with their PTH level. After surgery, PTH levels
were assumed to be controlled (PTH levels below
300 pg/ml) for 6 months and then they could increase
again and be treated with cinacalcet at the dose before
surgery. Patient history and the occurrence of multiple
complications were modeled by having patients enter
each cycle of the model in a speciﬁc health state deﬁned
by PTH levels and history of CVD hospitalization,
fracture, and parathyroidectomy. Risk factors for initial
and subsequent events (CVD, fracture or parathy-
roidectomy) were assumed to be the same regardless of
patient history. Nevertheless, if a patient experienced
multiple complications, the cumulative effect of reduc-
tion in quality of lifewas taken into account by applying
all corresponding quality of life utilities as multiplica-
tive factors to the patient’s current utility.
Event Rates and Risk Adjustments
Probabilities (by PTH category) for the occurrence of
complications were derived from clinical trial data,
when sample size permitted. When clinical trial data
were not available, information was derived from pub-
lished sources and a large US-based dialysis database
was used. The probability of a parathyroidectomy pro-
cedure (for each PTH level) was derived from the
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placebo arms of four pooled clinical trials which were
conducted in the USA, Europe, and Australia and con-
sisted of 487 patients that were randomly allocated to
receive placebo [29]. There were approximately 324
patient-years of exposure [29]. The probability of a
major fracture (for each PTH level) was derived from
published data from 9007 dialysis patients (included in
the Waves 1–4 of the Dialysis Morbidity and Mortality
Study). The probability of a major fracture (for each
PTH level) was derived from the pooled clinical trial
data using a weighted occurrence rate of hip, vertebral,
and pelvic fractures [29]. The model only made use of
hip, vertebral, and pelvic fractures as they were deter-
mined to have the largest impact on quality of life and
costs. The probability of a CVD event (for each PTH
level) was derived from a large US database of ESRD
dialysis patients.
Transition Probabilities
Transition probabilities within the model were used to
capture changes in PTH levels in both treatment arms.
In the early cinacalcet treatment arm, all patients
entered the model in the health state representing PTH
levels between 300 and 500 pg/ml and were assumed
to receive cinacalcet treatment at the beginning of
the simulation. Subsequently, 81% of patients were
assumed to reach the K/DOQI target range of PTH
levels below 300 pg/ml and were assumed to maintain
this PTH level for the remainder of the simulation. The
assumptions were based on pooled data from three,
similarly designed, 26-week clinical trials with a total of
1136 dialysis patients randomized to receive either
cinacalcet or placebo in addition to standard of care
[24], and an extension study with up to 3 years of
follow-up where patients on cinacalcet were shown to
maintain their response [35]. The maintenance data are
substantial when considering the life expectancy of
patients on dialysis is approximately 5 years. The
remaining proportion of patients in the early cinacalcet
treatment group (19%) were assumed to transition to
other PTH level health states at probabilities observed
in a national renal database and continued to receive
cinacalcet [36].
Similarly, in the delayed use of cinacalcet treatment
arm, all patients entered the model with PTH levels
between 300 and 500 pg/ml. The placebo arm of the
pooled clinical trial data was used to obtain the prob-
ability of transitioning to the K/DOQI target (below
300 pg/ml) [24]. Transitions to the other PTH levels
were obtained from a large US dialysis database [36].
Treatment with cinacalcet was initiated once patients
transitioned to the health state representing PTH levels
above 800 pg/ml, and continued to receive the medica-
tion until death or the patient underwent a parathy-
roidectomy procedure. Within the ﬁrst 6 months of
receiving cinacalcet therapy, there was a 22% probabil-
ity that patients would transition to the PTH level
health state below 300 pg/ml based on the pooled clini-
cal trial data, and would remain there for the duration
of the simulation [24,35]. The remaining proportion of
patients would transition to the other PTH level health
states at rates observed in the dialysis database.
Mortality
Estimates for the annual probability of death were
derived from the USRDS 2005 annual report, with
risks applied during each cycle and adjusted to increase
with age to reﬂect the increased mortality of patients
with ESRD (Table 1). To account for the increased risk
of death with higher PTH levels, PTH level-speciﬁc
relative risk of mortality rates reported by Block et al.,
derived from 40,538 dialysis patients in the USA, was
multiplied by the age-speciﬁc all-cause mortality to
calculate patients annual probability of death (Table 1)
[16].
Simulation Cohorts
Baseline cohort characteristics of simulated patients
included in the model were based on those included in
the clinical trials reported by Cunningham et al. All
patients were assumed to have ESRD, be treated with
either hemodialysis or peritoneal dialysis, and have
SHPT treated with standard care.
Costs
Costs were accounted in the analysis from the perspec-
tive of the third party health-care payer (Medicare) in
the USA (Table 2). Pharmacy costs of cinacalcet and
the costs associated with the occurrence of complica-
tions attributed to SHPT in patients with ESRD were
included in the analysis. All costs were inﬂated to 2006
US dollars (as required) using the medical component
of the US consumer price index (http://www.bls.gov/
cpi/home.htm).
The average doses of cinacalcet applied in the model
were taken from the measured doses from the pooled
clinical trials [37–39]. Doses were determined by
Table 1 Mortality rates
Annual mortality rate per 1000 patient years at risk
Age (years) Mean (years) Standard error Reference
Below 19 68.8 8.25 [2]
20–44 101.7 3.32 [2]
45–64 173.9 3.78 [2]
65–74 286.4 6.93 [2]
Above 75 426.8 9.38 [2]
PTH level-based relative risk of death
PTH level Value (relative risk) Reference
Below 300 pg/ml 1.00 [16]
300–500 pg/ml 1.0613 [16]
500–800 pg/ml 1.1824 [16]
Above 800 pg/ml 1.1824 [16]
PTH, parathyroid hormone.
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whether patients transitioned to a PTH level health
state below 300 pg/ml immediately after the initiation
of the medication. The cost of a CVD hospitalization
was applied in the model using a weighted average of
complications as observed in the clinical trials. The
weighted frequency of each CVD event was matched
with the corresponding event costs derived from a
large database of ESRD patients. A similar method
was employed to derive the cost of a major fracture.
The individual costs of a hip, pelvic or vertebral frac-
ture were derived from Medicare claims data [35].
The costs of renal dialysis were not included in
the model because the modeling study focused on the
incremental costs of adding cinacalcet therapy and the
occurrence of complications (Fig. 1).
Utilities
Changes in quality of life associated with the condi-
tion of ESRD, SHPT, and the occurrence of events
were derived from multiple sources (Table 3). Quality
of life at baseline for all patients in the analysis was
derived from a European-based study estimating
utility values for patients treated with both peritoneal
and hemodialysis [40]. To capture the decrement
in quality of life associated with the occurrence of a
CVD event, patients’ current utility was multiplied by
0.97, which was the mean value of angina symptoms
[41,42]. To account for the disutility associated with a
major fracture, a multiplicative value of 0.90 was
applied in each subsequent year after the event which
was derived from a systematic review of health state
utilities of osteoporosis-related fractures [43]. In the
absence of speciﬁc disutility data associated with a
parathyroidectomy procedure, the surgical procedure
was assumed to impact quality of life as per reported
decrements for general surgery [44]. Reduced quality
of life associated with uncontrolled PTH levels was
incorporated into the analysis by multiplying the
overall utility at the end of each cycle by -5%, -10%,
and -15% for patients in the PTH level health states
of 301 to 500 pg/ml, 501 to 800 pg/ml, and above
800 pg/ml, respectively, after physician consultation.
The application of PTH level-speciﬁc utility values
was intended to reﬂect bone pain, a common symp-
tom associated with hyperparathyroidism.
Discounting and Time Horizon
All costs and clinical beneﬁts were discounted at an
annual rate of 3.0% in the base case analysis to cor-
respond with current recommendations for health eco-
nomic analyses in the US setting [45,46]. A patient
lifetime horizon was used to capture all costs and
events associated with the progression of SHPT in the
simulation cohort.
Sensitivity Analyses
Sensitivity analyses were performed to investigate the
impact of key input parameters and assumptions on
the results of the base case analysis. The following
Table 2 Summary of input cost data
Variable Cost Reference
CV hospitalization and follow-up $20,001 23,159 [52]
Major fracture and follow-up $19,818 21,509 [34]
Parathyroidectomy and follow-up $15,247 13,715 [52]
PTH test $15.60 [53]
Cost of cinacalcet (per mg) $0.374 (Data provided by Amgen)
CV, cardiovascular; PTH, parathyroid hormone.
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(Rates determined by 
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Figure 1 Model diagram. CV, cardiovascular; PTH, parathyroid hormone;
PTx, parathyroidectomy.
Table 3 Quality of life utilities
Event Utility Reference
ESRD state utility 0.6735 (0.58–0.78) [40]
CVD hospitalization ¥0.97 [41,42]
Major fracture ¥0.90 [43]
300–500 pg/ml ¥0.95 Assumption
500–800 pg/ml ¥0.90 Assumption
Above 800 pg/ml ¥0.85 Assumption
CVD, cardiovascular disease; ESRD, end-stage renal disease.
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sensitivity analyses were performed: 1) the annual rate
used to discount future costs and clinical beneﬁts was
varied between 0 and 6% per annum; 2) the dose of
cinacalcet was varied by applying a multiplier to the
dose in both treatment arms by 20%; 3) adjusting
the annual mortality rate of patients with ESRD by
20%; 4) baseline event rates for both CVD and
fracture events were varied by 20%; 5) utility esti-
mates applied to the three levels of uncontrolled PTH
levels were removed; 6) after a parathyroidectomy,
patients were assumed to not continue receiving cina-
calcet treatment 6 months after surgery; and 7) proba-
bilistic sensitivity analysis was performed, involving
1000 random samples from the distributions between
the lower and upper bounds of 95% conﬁdence inter-
vals for clinical event rates, effectiveness, dosages of
cinacalcet, costs, and utilities. This was in contrast to
the deterministic calculation method applied in the
base case analysis, which used mean or most likely
values for the input parameters.
Results
Clinical Outcomes
In the base case analysis, early treatment with cinacal-
cet was projected to improve mean discounted quality-
adjusted life expectancy by 0.337 quality-adjusted life
years (QALYs) (3.002 vs. 2.665 QALYs) compared
to late treatment with cinacalcet (Table 4). Similar
improvements in life expectancy were estimated for
early versus late cinacalcet treatment (4.638 vs.
4.372 years, difference of 0.266 years). Undiscounted
life expectancy was estimated to be 5.294 years for
early cinacalcet treatment and 4.961 years with late
treatment, an improvement of 0.334 years.
Economic Outcomes
Early cinacalcet treatment was projected to result in
total direct medical costs (discounted at 3% per
annum) of $98,499 compared to $92,674 for patients
treated with late cinacalcet, an increase of $5825 over
patient lifetimes (Table 4). Medication costs of cinacal-
cet were projected to account for 50% of total costs in
the early treatment arm and 46% in the late treatment
arm over patient lifetimes.
Early treatment with cinacalcet was associated with
higher medication costs, and because of the increased
life expectancy, slightly higher CVD, and fracture
treatment costs compared to late treatment. Neverthe-
less, these costs were partially offset by a reduction in
the costs of patients undergoing a parathyroidectomy
procedure because of lower PTH levels. Increased costs
of treating CVD and fracture complications were
attributed to the survival paradox, whereby patients in
the early cinacalcet arm lived longer and, although
these patients were more likely to achieve controlled
PTH levels than late treatment (resulting in lower CVD
event rates), patients were exposed to the risk of com-
plications for a longer time period, leading to higher
complication costs.
Cost-Effectiveness
The incremental cost-effectiveness ratio (ICER) was
estimated to be $17,275 per QALY gained for early
versus late cinacalcet treatment, when total direct
medical costs were taken into account. When only
medication costs were considered, early cinacalcet
treatment was projected to result in an ICER of
$20,860 per QALY gained, compared to late cinacalcet
treatment. When life expectancy was considered
(rather than quality-adjusted life expectancy), the
ICER was $21,881 per life year gained for early versus
late cinacalcet treatment.
Sensitivity Analyses
Sensitivity analysis performed on key input parameters
in the base case analysis indicated that the results were
robust under variation within a range of plausible
assumptions (Table 5). Varying the annual rate used to
discount future costs and clinical beneﬁts between 0
and 6% (base case 3%) had little impact on the ICER.
When outcomes were not discounted, early treatment
with cinacalcet was projected to remain cost-effective
compared to late treatment, with an ICER of $13,018
per QALY gained. Applying a discount rate of 6% to
all clinical and economic outcomes increased the ICER
to $21,723 per QALY gained for early versus late
cinacalcet treatment.
When the average dose of cinacalcet was reduced
by 20% in both treatment arms, the ICER was reduced
to $13,103 per QALY gained, whereas increasing the
average dose in both treatment arms, increased the
ICER to $21,447 per QALY gained for early versus
late cinacalcet treatment. A similar analysis was
Table 4 Base case results
Early cinacalcet Late cinacalcet Difference
Quality-adjusted life expectancy 3.002 2.665 0.337
Life expectancy 4.638 4.372 0.266
Total costs $98,499 $92,674 $5825
ICER (with quality-adjusted life expectancy) $17,275 per QALY gained
ICER (with life expectancy) $21,881 per life year gained
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year.
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performed by varying overall ESRD mortality rates by
20%. Increasing and decreasing the overall mortality
rate by 20% produced ICERs of $8526 and $24,722
per QALY gained, respectively, for early versus late
cinacalcet treatment over patient lifetimes.
To determine the impact of changes in CVD com-
plication rates on ﬁnal outcomes, CVD rates were
reduced 20% in a sensitivity analysis. This produced
an ICER of $17,015 per QALY gained. Increasing the
risk of CVD complications by 20% generated an ICER
of $17,521 per QALY gained for early versus late
cinacalcet treatment. Similarly, variation in the rate
of fractures had relatively little impact on overall out-
comes. When the rate of fractures was varied by the
same proportions, the ICERs for early versus late cina-
calcet treatment varied between $17,103 and $17,445
per QALY gained over patient lifetimes.
Sensitivity analysis was also performed by removing
disutility values applied in the base case analysis to
explicitly account for increasing levels of bone pain in
patients with uncontrolled PTH levels (above 300 pg/
ml). When these disutility values were removed, the
ICER increased to $33,557 per QALY gained for early
versus late cinacalcet treatment.
In the base case analysis, patients were assumed to
resume their previous dose of cinacalcet treatment
6 months (one cycle) after a parathyroidectomy, in both
treatment arms. In a sensitivity analysis where patients
were assumed to not receive cinacalcet treatment after a
parathyroidectomy, the ICER increased to $30,897 per
QALY gained for early versus late cinacalcet treatment.
Probabilistic sensitivity analysis (second-order
Monte Carlo simulation) was also performed which
involves random sampling between the lower and
upper bounds of the 95% conﬁdence intervals for
clinical event rates, effectiveness, dosages of cinacalcet,
costs, and utilities. Sampling did not substantially
change the outcomes of the base case analysis where
a deterministic approach (mean values) had been used.
When 1000 mean values of incremental costs versus
incremental effectiveness in terms of quality-adjusted
life expectancy were plotted on a scatter-plot diagram,
a majority of the points fell in the upper right quadrant
of the cost-effectiveness plane, indicating increased
costs and increased effectiveness. These mean values
were used to generate an acceptability curve over a
range of willingness to pay values which indicated that
there was about a 99% probability that early cinacal-
cet treatment compared to later treatment (both in
addition to standard care) would be considered cost-
effective assuming a willingness to pay of $50,000 per
QALY gained (Fig. 2) [47].
Discussion
Cinacalcet is the only drug currently available shown to
lower all four mineral metabolism biomarkers (PTH,Ta
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Ca, P, Ca ¥ P) [48] linked to CV morbidity and mortal-
ity [4,15,16,18,19,49]. Although use of cinacalcet is
currently skewed toward patients with higher PTH
levels, clinical trial results suggest there is sound clinical
rationale for early use, and the results from the present
analysis indicate that early treatment with cinacalcet is
likely to be cost-effective compared to delaying treat-
ment [24]. Initiation of treatment with cinacalcet when
PTH levels were 300 to 500 pg/mL was estimated to
increase both life expectancy and quality-adjusted life
expectancy compared to treatment when PTH levels
were above 800 pg/mL. Improvements in clinical out-
comes were driven by PTH level-speciﬁc risk factors of
developing complications and mortality and the larger
proportion of patients achieving controlled PTH levels
in the early cinacalcet treatment arm. Early treatment
with cinacalcet was also associated with higher treat-
ment costs. Nevertheless, with projected ICERs of
$17,275 per QALY gained to $21,881 per life year
gained, the present analysis indicated that early cinacal-
cet use is likely to be a cost-effective treatment option in
the USA, compared to late treatment. This ICER is well
below cost-effectiveness thresholds commonly refer-
enced to indicate good value for money in the USA [47].
The concusions of the model are robust under varia-
tion in a wide range of assumptions. Sensitivity analy-
ses revealed that outcomes from the model, in terms of
cost per QALY gained for early versus late cinacalcet
treatment, were most sensitive to reductions in mortal-
ity risk because of ESRD, removal of quality of life
utilities for PTH levels, and assumptions regarding the
continuation of cincacalcet treatment after a parathy-
roidectomy. Nevertheless, the corresponding ICERs in
terms of cost per QALY gained were still within the
range generally considered good value for money.
The costs associated with renal dialysis were not
accounted for in the analysis. Had the considerable
costs associated with renal dialysis been modeled, this
may have biased against early cinacalcet because
patients receiving this additional treatment tended to
live longer, on average, and so would have accrued
greater dialysis costs attributing to the so-called “sur-
vivor effect.” A similar effect was seen with CVD and
fracture costs, the early cinacalcet treatment arm,
where the total costs attributed to treating these two
complications were lower in shorter time horizons
because of the increased life expectancy.
As with most health economic modeling analyses,
certain assumptions were required to facilitate the
modeling process. One assumption used in the primary
analysis was that the risk of a subsequent fracture was
not increased in patients who experienced an initial
major fracture. No evidence was identiﬁed indicating
that fracture risks would differ between initial and
subsequent events and therefore the analysis assumed
that there would be no difference. Similarly, any
increased risk of a cardiovascular hospitalization sub-
sequent to undergoing a parathyroidectomy procedure
or incurring a major fracture was not known, and
therefore not included in the analysis. Nevertheless,
parathyroidectomy is rarely performed in patients with
secondary renal hyperparathyroidism and remains an
intervention of last resort [49,50]. It is known that
parathyroidectomy is accompanied by a 1.5- to 2.7-
fold increased risk of death during the ﬁrst 3 months
after surgery, accompanied by a decline in death rates
toward 10% below the mortality rate observed in
matched controls [49]. In the present analysis, the risk
of death immediately after a parathyroidectomy was
assumed to be 2.1 times higher than general ESRD
mortality. Additionally, calciﬁcation in other soft
tissues was not modeled which although very rare is a
serious complication and associated with high degree
of mortality.
The increased risk of death after a CVD or fracture
event was not accounted for in the analysis. Mortality
was assumed to be the same regardless of a patient’s
history of complications (except immediately after a
parathyroidectomy) and was instead dependent upon
patient age and PTH level. This assumption is likely to
have favored late cinacalcet treatment as patients in
the higher PTH levels experienced more CVD and
fracture events.
A health economic model of cinacalcet treatment
in the UK setting has been previously published by
Garside et al. [51] where the authors concluded that
cinacalcet treatment was unlikely to be cost-effective in
the UK under the assumptions used to construct their
model. It is noteworthy, however, that this was not the
view of NICE in the recently published technology
appraisal guidance (no. 117) where cinacalcet was
indeed recommended for funding. Published literature
has demonstrated a link between higher PTH levels
and mortality [16]. The Garside model does not take
this into account, whereas the current model does.
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Despite acknowledging that bone pain and pruritis
are common symptoms of hyperparathyroidism, the
Garside model only applies a decrement in health state
utility to “very uncontrolled” PTH levels (a value
which is consistent with the current model), whereas
the current model applies a gradually increasing health
state utility decrement as PTH levels increase above an
uncontrolled state.
In summary, this economic model suggests that it is
cost-effective to initiate treatment with cinacalcet as
soon as patients’ PTH levels rise above 300 pg/ml
rather than delaying treatment until their PTH levels
are severely out of control.
We would like to acknowledge the collaboration and com-
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